Announcement • May 29
Pharvaris Presents Clinical Data and Product Pipeline Updates At Eaaci Annual Congress 2026 Pharvaris announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the European Academy of Allergy and Clinical Immunology Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey. Title: Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial. Format: Oral Presentation. Title: Clinical Cardiovascular Safety Assessment of Oral Deucrictibant. Format: Poster Presentation. Title: A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema. Format: Poster Presentation. Title: Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule. Format: Poster Presentation. Title: Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial. Format: Poster Presentation. Title: RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks. Format: Poster Presentation. Title: Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema. Format: Flash Talk. Title: CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema. Format: Flash Talk. The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations. Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. PHVS
Live News • May 10
Pharvaris Targets US$115 Million to Advance Lead Drug Deucrictibant in Late-Stage Trials Pharvaris has priced an underwritten offering expected to raise about US$115 million in gross proceeds.
The company is issuing 3,874,664 ordinary shares, with underwriters holding a 30-day option to buy up to an additional 581,199 shares at the same price.
Management plans to use the funds to support clinical development and marketing authorization applications for lead asset deucrictibant in bradykinin-mediated diseases.
For you as an investor, this capital raise means Pharvaris is adding a sizeable cash buffer to support its late-stage pipeline work. The offering is tied directly to advancing deucrictibant, an oral bradykinin B2 receptor antagonist, through clinical programs and regulatory filings, which are typically costly phases for a late-stage biopharmaceutical company.
The flip side is that issuing new shares increases the overall share count, which can dilute existing holdings. If you follow Pharvaris, it is worth watching how efficiently this new capital is deployed across trials and marketing authorization efforts, and tracking any updates on clinical milestones or regulatory submissions related to deucrictibant. Announcement • May 10
Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $115.000028 million. Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $115.000028 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,874,664
Price\Range: $29.68
Discount Per Security: $1.7808 
